Eli Lilly and Company (LLY) Q1 2026 (USD): Adj. EPS 8.55 (exp. 6.88), Revenue 19.8bln (exp. 17.68bln), Mounjaro 8.66bln, Zepbound 4.16bln

Newsquawk StaffPublished
Newsquawk headlinesUTC

Every headline is on the live feed 20 minutes before this site.

Quanta Services Inc. (PWR) Q1 2026 (USD): Adj. EPS 2.68 (exp. 2.04), Revenue 7.9bln (exp. 7.00bln), Adj. EBITDA 686.4mln (exp. 572.4mln)

PREVIEW: BoE Policy Announcement & MPR due at 12:00BST/07:00EDT on Thursday, 30th April 2026

Eli Lilly and Company (LLY) Q1 2026 (USD): Adj. EPS 8.55 (exp. 6.88), Revenue 19.8bln (exp. 17.68bln), Mounjaro 8.66bln, Zepbound 4.16bln

Smurfit Westrock (SWR LN) says that it undertakes a review of its LSE listing, adding that a delisting is possible

Royal Caribbean Group (RCL) Q1 2026 (USD): Adj. EPS 3.48 (exp. 3.22), Revenue 4.45bln (exp. 4.46bln)

On the Newsquawk feed at , 20 minutes before this page.

Use the PlatformFree. No signup, no card.

Guidance

  • FY adj. EPS 35.50-37 (exp. 34.52).
  • FY revenue 82-85bln (exp. 82.1bln).

Context

Eli Lilly's strong Q1 results, with an adjusted EPS and revenue significantly beating expectations, indicate robust performance driven by key products like Mounjaro and Zepbound. This outperformance, coupled with positive full-year guidance, suggests strong momentum in the pharmaceutical sector, which may bolster investor sentiment towards the stock. Traders should consider potential upward revisions in earnings expectations and implications for sector peers.

Related headlines

The feed had this first.

Use the Platform